•Gross business wins in the quarter of $2,966 million, representing an increase of 10.6% on quarter one 2025.

•Net business wins in the quarter of $2,057 million; a net book to bill in the quarter of 1.02.

•Quarter two revenue was $2,017.4 million representing an increase of 0.8% on quarter one 2025.

•Net income for the quarter was $183.0 million or $2.30 per diluted share, an increase of 30.7% on quarter two 2024 diluted earnings per ordinary share.

•Quarter two adjusted EBITDA was $396.0 million or 19.6% of revenue, representing an increase of 1.4% on quarter one 2025.

•Quarter two adjusted net income was $259.5 million or $3.26 per diluted ordinary share.

•Net debt was $3.0 billion at June 30, 2025 with a net debt to adjusted EBITDA ratio of 1.9x.

•$250.0 million worth of stock repurchased in quarter two at an average price of $146 per share.

•Board of Directors authorized expansion of $500 million to current share repurchase program, bringing the remaining total value of authorized share repurchases to $1 billion to be opportunistically deployed.

•Amending full-year 2025 financial revenue guidance to a range of $7,850 - $8,150 million, an increase of $50 million at the midpoint from the prior full-year guidance range. Updating full-year 2025 adjusted diluted earnings per share* guidance to a range of $13.00 - $14.00. Adjusted diluted earnings per share to exclude amortization, stock compensation, restructuring, foreign exchange, transaction-related / integration-related adjustments and their related taxation effect.

Dublin, Ireland, July 23, 2025 – ICON plc (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today reported its financial results for the second quarter ended June 30, 2025.

CEO, Dr. Steve Cutler commented, “ICON made solid progress in quarter two despite the continuing challenges within the clinical development and macro-economic environments. ICON’s innovative solutions continue to resonate with customers, leading to strong progression in gross business wins in the quarter, which increased 11% sequentially over quarter one.

We are updating our full-year financial guidance and now expect full-year revenue to be in the range of $7,850 - $8,150 million, an increase of approximately 1% at the midpoint from our prior full-year revenue guidance range. Additionally, we expect adjusted diluted earnings per share to be in the range of $13.00 - $14.00, reflecting increased pass-through revenue expectations, alongside continued strong cost management across our business."

Gross business wins in the second quarter were $2,966 million and cancellations were $909 million. This resulted in net business wins of $2,057 million and a book to bill of 1.02.

Revenue for the second quarter was $2,017.4 million. This represents a decrease of 4.8% on quarter two 2024 or a 5.6% decrease on a constant currency basis.

GAAP net income was $183.0 million, resulting in $2.30 diluted earnings per share in quarter two 2025 compared to $1.76 diluted earnings per share in quarter two 2024, an increase of 30.7% year over year. Adjusted net income for the quarter was $259.5 million, resulting in an adjusted diluted earnings per share of $3.26 compared to $3.75 per share for the second quarter 2024.

Adjusted EBITDA for the second quarter was $396.0 million or 19.6% of revenue, a decrease of 12.1% on quarter two 2024.

The effective tax rate on adjusted net income in quarter two 2025 was 16.5%.

Cash generated from operating activities for the quarter was $146.2 million. During the quarter $32.3 million was spent on capital expenditure. $250.0 million worth of stock was repurchased at an average price of $146 per share. Additionally, $7.4 million of Term Loan B payments were made during the quarter. At June 30, 2025, the Group had cash and cash equivalents of $390.4 million, compared to cash and cash equivalents of $526.7 million at March 31, 2025 and $506.6 million at June 30, 2024. Net indebtedness as at June 30, 2025 was $3.0 billion.

Gross business wins year to date were $5,647 million and cancellations were $1,568 million. This resulted in net business wins of $4,079 million and a book to bill of 1.01.

Revenue year to date was $4,018.7 million. This represents a year on year decrease of 4.6% or 4.4% on a constant currency basis.

GAAP net income year to date was $337.1 million, resulting in $4.20 diluted earnings per share. Year to date adjusted net income was $517.8 million, resulting in an adjusted diluted earnings per share of $6.45 compared to $7.22 per share for the equivalent prior year period.

Adjusted EBITDA year to date was $786.7 million or 19.6% of revenue, a year on year decrease of 12.0%.

The effective tax rate on adjusted net income year to date was 16.5%.

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this press release contains certain non-GAAP financial measures, including adjusted EBITDA, adjusted net income and adjusted diluted earnings per share. Adjusted EBITDA, adjusted net income and adjusted diluted earnings per share exclude amortization, stock compensation, foreign exchange gains and losses, restructuring, transaction-related / integration-related adjustments and their related taxation effect. While non-GAAP financial measures are not superior to or a substitute for the comparable GAAP measures, ICON believes certain non-GAAP information is useful to investors for historical comparison purposes.

ICON will hold a conference call on July 24, 2025 at 08:00 EDT [13:00 Ireland & UK]. This call and linked slide presentation can be accessed live from our website at http://investor.iconplc.com. A recording will also be available on the website for 90 days following the call. In addition, a calendar of company events, including upcoming conference presentations, is available on our website, under “Investors”. This calendar will be updated regularly.

This press release contains forward-looking statements, including statements about our financial guidance. These statements are based on management's current expectations and information currently available, including current economic and industry conditions.  These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release.  The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as other economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, F-4, S-8, F-3 and certain other reports, which are available on the SEC's website at http://www.sec.gov.

* Our full-year 2025 guidance adjusted diluted earnings per share measures are provided on a non-GAAP basis because the company is unable to predict with a reasonable degree of certainty certain items contained in the GAAP measures without unreasonable efforts. For the same reasons, the company is unable to address the probable significance of the unavailable information.

ICON plc is a world-leading clinical research organization powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 39,900 employees in 95 locations in 55 countries as at June 30, 2025. For further information about ICON, visit: www.iconplc.com.

Source: ICON plc

Contact: Investor Relations +1 888 381 7923

Nigel Clerkin Chief Financial Officer +353 1 291 2000

Kate Haven Vice President Investor Relations +1 888 381 7923

All at ICON

ICON/ICLR-F

			Six Months Ended
			June 30, 2025						June 30, 2024
			(in thousands)
Cash flows provided by operating activities:
Net income			$	337,123					$	334,348
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization expense			193,676						298,816
Impairment of operating right-of-use assets and related property, plant and equipment			5,573						12,559
Reduction in carrying value of operating right-of-use assets			18,977						19,367
Amortization of financing costs and debt discount			2,971						20,604
Stock compensation expense			27,610						28,145
Deferred tax benefit			(46,095)						(61,239)
Unrealized foreign exchange movements			34,777						13,761
Other non-cash items			15,266						12,463
Changes in operating assets and liabilities:
Accounts receivable			24,374						198,749
Unbilled revenue			36,040						(287,183)
Unearned revenue			(122,306)						(52,081)
Other net assets and liabilities			(113,545)						7,356
Net cash provided by operating activities			414,441						545,665
Cash flows used in investing activities:
Purchase of property, plant and equipment			(61,185)						(63,440)
Purchase of subsidiary undertakings (net of cash acquired)			(2,537)						(7,831)
Movement of available for sale investments			—						1,954
Proceeds from investments in equity			561						1,373
Purchase of investments in equity			(12,330)						(5,621)
Net cash used in investing activities			(75,491)						(73,565)
Cash flows used in financing activities:
New Notes issue costs			—						(11,679)
Drawdown of credit lines and loan facilities			50,000						2,192,480
Repayment of credit lines and loan facilities			(64,881)						(2,537,882)
Proceeds from exercise of equity compensation			6,498						21,645
Share issue costs			(9)						(14)
Repurchase of ordinary shares			(500,000)						—
Share repurchase costs			(300)						—
Net cash used in financing activities			(508,692)						(335,450)
Effect of exchange rate movements on cash			21,353						(8,199)
Net (decrease) / increase in cash and cash equivalents			(148,389)						128,451
Cash and cash equivalents at beginning of period			538,785						378,102
Cash and cash equivalents at end of period			$	390,396					$	506,553

    

(a)Stock-based compensation expense represents the amount of expense related to the company’s equity compensation programs (inclusive of employer related taxes).

(b)Foreign currency losses/(gains), net relates to losses or gains that arise in connection with the revaluation, or settlement, of non-US dollar denominated assets and liabilities. We exclude these losses and gains from adjusted EBITDA and adjusted net income because fluctuations from period- to- period do not necessarily correspond to changes in our operating results.

(c)Restructuring relates to charges incurred in connection with the company's realignments of its workforce, with the elimination of redundant positions as well as reviewing its global office footprint and optimizing its locations to best fit the requirements of the company.

(d)Transaction and integration related costs include expenses associated with our acquisitions and any other costs incurred directly related to the integration of these acquisitions.

(e)Transaction-related financing costs includes costs incurred in connection with changes to our long-term debt and amortization of financing fees. We exclude these costs from adjusted EBITDA and adjusted net income because they result from financing decisions rather than from decisions made related to our ongoing operations.

(f)Represents the tax effect of adjusted pre-tax income at our estimated effective tax rate.